Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Previously Untreated CD123+ AML
NCT06456463Phase 2Active, not recruiting
- Sponsor
- Stemline Therapeutics
- Start
- Jan 2025
- Primary completion
- Feb 2028
- Countries
- 2
01
Overview
A Phase 2 trial of tagraxofusp in acute myeloid leukemia (AML), sponsored by Stemline Therapeutics. Started Jan 2025; status: active, not recruiting.
02
Drugs
tagraxofusp
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06456463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06456463.